SCHEMBL25523341

SCHEMBL25523341

Pc1cccnc1CNCc1ccc(Br)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CCR5 P51681 1/20 0.36
CHRM2 P08172 1/20 0.36
KMT2A Q03164 2/20 0.33
GRM2 Q14416 1/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
PKM P14618 1/20 0.32
GBA1 P04062 1/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
POLB P06746 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31064643 0.84 KDM1A (0.39) RXFP1L3MBTL1CCR5CHRM2KMT2A
SCHEMBL25523333 0.84 IGF1R (0.38) RXFP1L3MBTL1CCR5CHRM2RAB9A
SCHEMBL30707605 0.71 GBA1 (0.47) CCR5KMT2AGRM2RAB9ASMN1; SMN2
SCHEMBL25522223 0.69 SCN8A (0.39) CHRM2
SCHEMBL30707715 0.69 KMT2A (0.45) L3MBTL1CCR5KMT2ARAB9ASMN1; SMN2
SCHEMBL28399733 0.68 GBA1 (0.39) CHRM2GRM2RAB9ASMN1; SMN2NPC1
SCHEMBL25203464 0.67 OPRM1 (0.43) GRM2RAB9ASMN1; SMN2NPC1PKM
SCHEMBL30707664 0.67 OPRM1 (0.43) GRM2RAB9ASMN1; SMN2NPC1PKM
SCHEMBL31419049 0.67 GBA1 (0.40) RXFP1L3MBTL1KMT2AGRM2RAB9A
SCHEMBL25523327 0.67 ADORA2A (0.41) RAB9ASMN1; SMN2NPC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RXFP1 2081/4885L3MBTL1 1934/4885CCR5 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.